Grange F, Mohr P, Harries M, Ehness R, Benjamin L, Siakpere O, Barth J, Stapelkamp C, Pfersch S, McLeod LD, Kaye JA, Wolowacz S, Kontoudis I. Economic burden of advanced melanoma in France, Germany, and the UK: a retrospective observational study (Melanoma Burden-of-Illness Study). Melanoma Res. 2017 Dec;27(6):607-18. doi: 10.1097/CMR.0000000000000372
Wolowacz S, Briggs A, Lloyd A, Doward L. Collecting health-state utility estimates for economic models in clinical studies. Presented at the 2017 ISPOR 20th Annual European Congress; November 4, 2017. Glasgow, Scotland. Previously presented at the ISPOR 19th Annual European Congress.
Wolowacz S, Mauskopf J, Earnshaw SR. Determining the analytic framework. In: Mauskopf J, Earnshaw SR, editors. Budget-impact analysis of health care interventions: a practical guide. 1st ed. Cham: Switzerland. Springer International Publishing AG; 2017. p.11-34. doi: 10.1007/978-3-319-50482-7
Wolowacz S, Mauskopf J, Earnshaw SR. Estimating condition-related costs. In: Mauskopf J, Earnshaw SR, editors. Budget-impact analysis of health care interventions: a practical guide. 1st ed. Cham: Switzerland. Springer International Publishing AG; 2017. p.91-101. doi: 10.1007/978-3-319-50482-7
Mauskopf J, Wolowacz S, Earnshaw SR. Alternative interventions. In: Mauskopf J, Earnshaw SR, editors. Budget-impact analysis of health care interventions: a practical guide. 1st ed. Cham: Switzerland. Springer International Publishing AG; 2017. p.203-16. doi: 10.1007/978-3-319-50482-7
Muszbek N, Benedict A, Wolowacz S. Health economic modeling in oncology. Presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. Previously presented at the ISPOR 19th Annual European Congress.
Wolowacz S, Briggs A, Lloyd AJ, Doward L. Collecting health-state utility estimates for economic models in clinical studies. Presented at the 2017 ISPOR 22nd Annual International Meeting; May 21, 2017. Boston, MA. Previously presented at the ISPOR 19th Annual European Congress.
Harries M, Mohr P, Grange F, Ehness R, Benjamin L, Siakpere O, Barth J, Stapelkamp C, Pfersch S, McLeod L, Wolowacz S, Kaye JA, Kontoudis I. Treatment patterns and outcomes of Stage IIIB/IIIC melanoma in France, Germany and the UK: a retrospective and prospective observational study (MELABIS). Int J Clin Pract. 2017 May 16;71(5):e12946. doi: 10.1111/ijcp.12946
Brockbank J, Wolowacz S. Economic evaluations of new oral anticoagulants for the prevention of venous thromboembolism after total hip or knee replacement: a systematic review. Pharmacoeconomics. 2017 May;35(5):517-35. doi: 10.1007/s40273-017-0486-4
Zuluaga S, Hess LM, Wolowacz S, Dyachkova Y, Hawe E, Vickers AD, Kaye JA, Bertwistle D. Cost-effectiveness of olaratumab in combination with doxorubicin for the treatment of locally advanced or metastatic soft tissue sarcoma in the United States. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A108.
Wolowacz S. Editorial: ISPOR good research practices task force report—mapping to estimate utility values from non–preference-based outcome measures. Value Health. 2017 Jan;20(1):28-9. doi: 10.1016/j.jval.2016.11.026
Wolowacz S. New ISPOR recommendations - mapping methods for estimation of health state utility. Value Health. 2017 Jan;20(1):28-9. doi: 10.1016/j.jval.2016.11.026